Translational science approach for assessment of cardiovascular effects and proarrhythmogenic potential of the beta-3 adrenergic agonist mirabegron
- 1 September 2017
- journal article
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 87, 74-81
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeysNaunyn-Schmiedeberg's Archives of Pharmacology, 2013
- Preclinical Torsades-de-Pointes Screens: Advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic riskPharmacology & Therapeutics, 2008
- In vitro models of proarrhythmiaBritish Journal of Pharmacology, 2008
- The impact of varying autonomic states on the dynamic beat‐to‐beat QT–RR and QT–TQ interval relationshipsBritish Journal of Pharmacology, 2008
- Use and abuse of QT and TRIaD in cardiac safety research: Importance of study design and conductEuropean Journal of Pharmacology, 2008
- Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmiasHeart Rhythm, 2006
- β3-Adrenoceptors in the heartCardiovascular Research, 2002
- β3-Adrenergic regulation of an ion channel in the heart—inhibition of the slow delayed rectifier potassium current IKs in guinea pig ventricular myocytesCardiovascular Research, 2002
- Functional beta3-adrenoceptor in the human heart.Journal of Clinical Investigation, 1996
- Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patchesPflügers Archiv - European Journal of Physiology, 1981